Page 5 of 5
ACS Medicinal Chemistry Letters
(8) Johnson, C. N.; Ahmed, M.; Miller, N. D. 5ꢀHT6 receptor
substituted 1,2,3,4ꢀtetrahydroꢀßꢀcarbolines. Pharmazie
1
2
3
4
5
6
7
8
9
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
6
antagonists: prospects for the treatment of cognitive
disorders including dementia. Curr. Opin. Drug Discov.
Devel. 2008, 11, 642–654.
1993, 48, 289–294. 17b) Paluchowska, M. H.; Bugno, R.;
Duszynska, B.; Tatarczynska, E.; Nikiforuk, A.; Lenda, T.;
ChojnackaꢀWójcik, E. The influence of modifications in
imide fragment structure on 5ꢀHT1A and 5ꢀHT7 receptor
affinity and in vivo pharmacological properties of some new
(
9) Hirano, K.; Piers, T. M.; Miller, N. D.; Rutter, A. R.;
Chapman, P. F. Procognitive 5ꢀHT6 antagonists in the rat
forced swimming test: potential therapeutic utility in mood
disorders associated with Alzheimer's disease. Life Sci.
1ꢀ(mꢀtrifluoromethylphenyl)piperazines.
Bioorg. Med.
Chem. 2007, 15, 7116–7125. 17c) Zajdel, P.; Marciniec, K.;
Maslankiewicz, A.; Satala, G.; Duszynska, B.; Bojarski, A.
J.; Partyka, A.; JastrzbskaꢀWisek, M.; Wróbel, D.;
Wesolowska, A.; Pawlowski, M. Quinolineꢀ and
isoquinolineꢀsulfonamide derivatives of LCAP as potent
2
009, 84, 558–562.
(10) Ivachtchenko, A. V.; Ivanenkov, Y. A.; Tkachenko, S. E. 5ꢀ
Hydroxytryptamine subtype 6 receptor modulators: A patent
survey. Expert Opin. Ther. Pat. 2010, 20, 1171–1196.
11) Glennon, R. A.; Siripurapu, U.; Roth, B. L.; Kolanos, R.;
Bondarev, M. L.; Sikazwe, D.; Lee, M.; Dukat, M. The
medicinal chemistry of 5ꢀHT6 receptor ligands with a focus
on arylsulfonyltryptamine analogs. Curr. Top. Med. Chem.
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
(
CNS multiꢀreceptor
ꢀ
5ꢀHT1A/5ꢀHT2A/5ꢀHT7 and
D2/D3/D4 ꢀ Agents: The synthesis and pharmacological
evaluation. Bioorg. Med. Chem. 2012, 20, 1545–1556.
(18) Functional cAMP cellular assays at h5ꢀHT6Rs were
performed at Eurofins Cerep according to procedures
described online at www.cerep.fr.
(19) The percentage of inhibition for α1, α2C, H1, M1, M5, 5ꢀ
HT2B, 5ꢀHT2C, D3, hERG receptors and SerT for selected
compounds 28 and 30 were evaluated at Eurofins Cerep.
Experimental conditions for these assays are described
online at www.cerep.fr
2
010, 10, 579–595.
(
12) Ivachtchenko, A. V.; Ivanenkov, Y. A.; Skorenko, A.V. 5ꢀ
HT(6) receptor modulators: a patent update. Part 2.
Diversity in heterocyclic scaffolds. Expert Opin. Ther. Pat.
2012, 22, 1123–1168.
13) Cole, D. C.; Ellingboe, J. W.; Lennox, W. J.; Mazandarani,
H.; Smith, D. L. Stock, J. R.; Zhang, G.; Zhou, P.;
(
Schechter,
L.
E.
N1ꢀarylsulfonylꢀ3ꢀ(1,2,3,6ꢀ
(20) Ennaceur, A.; Delacour, J. A new oneꢀtrial test for
neurobiological studies of memory in rats. 1: Behavioral
data. Behav. Brain Res. 1988, 31, 47–59.
tetrahydropyridinꢀ4ꢀyl)ꢀ1Hꢀindole derivatives are potent and
selective 5ꢀHT6 receptor antagonists. Bioorg. Med. Chem.
Lett. 2005, 15, 379–383.
(
21) Popik, P.; Hołuj, M.; Nikiforuk, A.; Kos, T.; Trullas, R.;
Skolnick, P. 1ꢀaminocyclopropanecarboxylic acid (ACPC)
produces procognitive but not antipsychoticꢀlike effects in
rats. Psychopharmacology 2015, 232, 1025–1038.
(22) Porsolt, R. D.; Anton, G.; Blavet, N.; Jalfre, M. Behavioural
despair in rats: a new model sensitive to antidepressant
treatments. Eur. J. Pharmacol. 1978, 47, 379–391.
(14) Benhamú, B.; MartínꢀFontecha, M.; VázquezꢀVilla, H.;
Pardo, L.; LópezꢀRodríguez, M. L. Serotonin 5ꢀHT6
receptor antagonists for the treatment of cognitive
deficiency in Alzheimer’s disease. J. Med. Chem. 2014, 57,
7
160–7181.
(
15) Rosse, G. Quinoline derivatives as 5ꢀHT6 receptor PET
ligands. ACS Med. Chem. Lett. 2014, 5, 275–276.
16) Zajdel, P.; Masurier, N.; Canale, V.; Verdie, P.; Amblard,
M.; Pawłowski, M.; Martinez, J.; Subra, G. The pipecolic
(23) Detke, M. J.; Rickels, M.; Lucki, I. Active behaviors in the
rat forced swimming test differentially produced by
(
serotonergic
and
noradrenergic
antidepressants.
linker
ꢀ An acidꢀlabile handle for derivatization of
Psychopharmacology 1995, 121, 66–72.
secondary amines on a solidꢀsupport. Part 3. Tetrahedron
Letters 2013, 54, 998–1002.
(
24) Vogel, J. R.; Beer, B.; Clody, D. E. A simple and reliable
conflict procedure for testing antiꢀanxiety agents.
Psychopharmacology 1971, 21, 1–7.
25) Lacroix, L. P.; Dawson, L. A.; Hagan, J. J.; Heidbreder, C.
A. 5ꢀHT6 receptor antagonist SBꢀ271046 enhances
extracellular levels of monoamines in the rat medial
prefrontal cortex. Synapse 2004, 51, 158–164.
(
17) Radioligand binding assays were performed according to
the previously published procedures: 17a) Bojarski, A. J.;
Cegla, M. T.; CharakchievaꢀMinol, S.; Mokrosz, M. J.;
Mackowiak, M.; Misztal, S.; Mokrosz, J. L. Structureꢀ
activity relationship studies of CNS agents. Part 9: 5ꢀ
HT(1A) and 5ꢀHT2 receptor affinity of some 2ꢀ and 3ꢀ
(
Insert Table of Contents artwork here
ACS Paragon Plus Environment